C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).

Citation

• Rischin, D., Brungs, D., Day, F., Christie, H. R., Patel, V. A., Adams, G., . . . Porceddu, S. (2022). C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).. Journal of Clinical Oncology, 40(16_suppl), tps9592. doi:10.1200/jco.2022.40.16_suppl.tps9592

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.tps9592

Web Of Science Accession Number

Start Page

• tps9592

End Page

• tps9592

Volume

• 40

Issue

• 16_suppl

Place Of Publication

Abstract

UOW Authors

•   Brungs, Daniel

Publication Date

• 2022

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Rischin, D., Brungs, D., Day, F., Christie, H. R., Patel, V. A., Adams, G., . . . Porceddu, S. (2022). C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).. Journal of Clinical Oncology, 40(16_suppl), tps9592. doi:10.1200/jco.2022.40.16_suppl.tps9592

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.tps9592

Web Of Science Accession Number

Start Page

• tps9592

End Page

• tps9592

Volume

• 40

Issue

• 16_suppl

Place Of Publication